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ABSTRACT
The primary objective of this study was to compare health-related quality of life (HRQL) in adult patients
undergoing either ex vivo T cell–depleted bone marrow transplantation or conventional marrow transplanta-
tion. Data on patients’ HRQL were gathered as part of a multicenter randomized trial comparing the effect of
ex vivo T-cell depletion versus methotrexate and cyclosporine immunosuppression on disease-free survival.
HRQL assessments were conducted at baseline, day 100, 6 months, 1 year, and 3 years. There were no
treatment arm differences 1 year after transplantation on the Functional Assessment of Cancer Therapy, Bone
Marrow Transplantation, the Medical Outcomes Study Short-Form 36, and the Centers for Epidemiological
Studies of Depression. The lack of treatment differences was robust across types of data analyses that took
baseline functioning into account and that recognized the sensitivity of outcome measures to assumptions
concerning missing data. The trajectory of recovery revealed an initial decrease in function and then a recovery
to pretreatment levels that were similar for both treatment arms. Furthermore, the patients in both treatment
groups returned to a functional level that approximated general US population norms. Even though the
incidence of acute graft-versus-host disease was slightly higher in the conventional treatment arm, T-cell
depletion did not differentially affect HRQL at 1 year after transplantation.
© 2006 American Society for Blood and Marrow Transplantation
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mNTRODUCTION
Unrelated donor marrow transplantation offers a
ossible cure for patients with malignant diseases, but
t has high treatment-related morbidity and mortality.
cute and chronic graft-versus-host disease (GVHD)
re among the complications that may adversely affect
he transplantation patient’s health-related quality of
ife (HRQL). A treatment such as T-cell depletion
TCD) that reduces acute GVHD could improve
RQL through its effect on patient physical well- e
48eing. Among the potential advantages of TCD is the
educed need for prolonged posttransplantation im-
unosuppressant medication [1]. Others have reported
educed peritransplantation complications such as he-
atic veno-occlusive disease and pulmonary dysfunction
2-4] and a potentially greater likelihood of disease-free
urvival and cure [5].
The comparison of HRQL outcomes for varying
ethods of bone marrow transplantation (BMT) is
ssential to evaluate their relative costs and beneﬁts
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Health-Related Quality of Life after BMT
Bnd to provide information to patients regarding the
ffects of transplantation on all health-related aspects
f their lives: not just survival. Although some patients
xhibit few post-BMT complications, other patients
xperience a range of physical, psychological, and so-
ial difﬁculties. Reported post-BMT concerns include
ccupational disability, sexual dysfunction, cognitive im-
airment, emotional distress, chronic physical symp-
oms, and perceptions of poor health [6,7].
In 1995, the National Heart, Lung and Blood
nstitute funded a multicenter randomized trial that
xamined ex vivo TCD BMT versus conventional
MT. The primary ﬁndings of this trial [7] were that
CD did not differentially affect disease-free survival,
hronic GVHD, infections, relapse, or transplanta-
ion-related mortality measured at 3 years after trans-
lantation; there was a reduction in acute GVHD
mong patients who underwent TCD transplanta-
ions. Speciﬁcally, the time to the ﬁrst occurrence of
rade II to IV acute GVHD was signiﬁcantly delayed
mong recipients of TCD, and grades III and IV acute
VHD were reduced by TCD. The incidence of
cute GVHD among TCD patients at 100 days was
5% (HLA matched marrow) to 25% (1 antigen mis-
atched marrow); among non-TCD patients, it was
4% to 45%.
This study assessed the effect of these treatments
n HRQL. The primary analyses focused on treat-
ent differences in HRQL 1 year after transplanta-
ion, because that time point is most typically associ-
ted with “returning to normal” in studies of BMT
atients and is also the time when acute GVHD might
e expected to affect function. Secondary analyses for
he complete study sample were conducted to deter-
ine the longitudinal trajectory of HRQL scores across
ll assessment points. Additionally, patient function was
laced in a national, normative context for cancer
atients and for a general population to consider the
egree to which these patients have returned to nor-
al functioning.
In this study, HRQL was deﬁned multidimen-
ionally [8-11]. Life quality was assessed across 4
omains: physical health, personal and occupational
unctioning, interpersonal functioning, and psycho-
ogical distress and well-being. Additionally, life qual-
ty was assessed by using both disease-speciﬁc and
eneric measures. The use of generic measures allows
he experience of patients in this study to be compared
ith data provided by patients with chronic illnesses as
ell as a healthy age-matched group.
ETHODS
linical Trial
Between March 1995 and October 2000, 15 trans-
lantation centers enrolled 410 patients to evaluate the t
B&MTffects of 2 different methods of TCD of donor bone
arrow compared with conventional methotrexate/
yclosporine to prevent GVHD on 3-year disease-free
urvival. Of the 410 patients, 404 were considered to
e evaluable for acute GVHD; 5 patients died before
ransplantation, and 1 underwent transplantation 2
ears after enrollment (no acute GVHD information
as available). The conditioning regimen varied by
ype of GVHD prophylaxis. For elutriation centers,
onditioning was cyclophosphamide (CY) 120 mg/kg
ver 2 days and total body irradiation (TBI) 1320 to
375 cGy over 4 days for recipients of conventional
ransplants and an identical CY/TBI regimen plus
ntithymocyte globulin (ATGAM; Pharmacia, Kalama-
oo, MI) 90 mg/kg over 3 days for recipients of TCD
ransplants. For T10B9 centers, conditioning was CY
20 mg/kg over 2 days and TBI 1350 cGy over 5 days
or recipients of methotrexate/cyclosporine and CY
00 mg/kg over 2 days, cytosine arabinoside g/m2 over
days, and TBI 1410 cGy over 4 days for recipients of
CD grafts. Supportive care included antibiotics,
ransfusions, and pharmacologic drug management
tandardized according to the multicenter trial proto-
ol. A complete description of all clinical procedures
as been published [7].
ssessing HRQL
All consenting patients aged 18 years or older at
he time of randomization onto the main trial were
ligible for the adult HRQL component of the trial
which was reviewed and approved by institutional
eview boards). Baseline assessment interviews took
lace within 4 days before conditioning, typically once
he patient had arrived at the transplantation center.
osttransplantation interviews were scheduled at 100
ays, 6 months, 1 year, and 3 years. All interviews were
onducted by telephone, and patients received a pack-
ge of response materials before each interview. The
elephone interviews generally lasted 45 to 60 min-
tes, with the possibility of 2 sessions if the patient was
oo ill or tired to complete the interview in 1 session.
nterviews were conducted in English, but interpreta-
ion was possible for patients with language difﬁcul-
ies; 4 patients needed translators for a total of 5
nterviews.
nstruments
HRQL instruments were chosen according to em-
irical evidence of reliability, validity, and sensitivity
o differences over time, and published the availability
f normative data for comparison. Additionally, all
RQL instruments were pilot-tested to verify their
cceptability, efﬁciency, clarity, and face validity with
MT patients.
The disease-speciﬁc HRQL measure was the Func-
ional Assessment of Cancer Therapy (FACT) [12]. The
649
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6eneral version of the FACT is a 28-item self-report
uestionnaire that measures quality of life in cancer
atients. The FACT consists of 5 subscales that mea-
ure physical well-being, functional well-being, social/
amily well-being, emotional well-being, and satisfac-
ion with the doctor-patient relationship (the last
ubscale is no longer scored in most reported studies).
he BMT subscale of the FACT includes additional
tems speciﬁcally designed to test quality of life and
ymptoms speciﬁc to BMT patients [13]. Higher scores
ndicate a better quality of life. The FACT was scored by
sing the FACT manual version 3. FACT subscale
cores (as indicated previously) and 2 FACT total scores
FACT-G, 28 items; and FACT BMT total, 38 items)
ere obtained.
The mean and standard deviation of the baseline
ACT scores observed in the TCD trial were com-
arable to those observed in data gathered from 182
atients who completed the FACT-BMT at hospital
dmission [13]. Thus, our sample was similar in func-
ion to the standardization sample. The Cronbach ,
measure of the reliability of the instrument, was
omputed for each of the FACT domains and the
ggregate scores. The total scores used in the analyses
howed acceptable (.80) reliability.
The generic measure of HRQL was the Medical
utcomes Study Short-Form 36 (SF-36) [14]. The
F-36 is one of the most widely used health sta-
us inventories and assesses health domains relevant
o functional status and well-being. Eight health
oncepts are assessed: physical functioning, role limi-
ations due to physical health problems, bodily pain,
eneral health, energy, social functioning, emo-
ional functioning, and role limitations due to social/
motional problems. The SF-36 is scored on 2 major
imensions of health: physical health component sum-
ary (PCS) and mental health component summary
MCS). Higher values on the summary measures re-
ect better physical and mental health. Aggregate
CS and MCS scores were standardized by using a
score transformation to have a mean of 50 and an SD
f 10.
The Centers for Epidemiological Studies of
epression (CES-D) [15] was used to measure psy-
hological distress and well-being. The CES-D was
eveloped for use with physically ill persons and dif-
ers from traditional measures of depression because
f its lack of reliance on somatic indices of depression.
igher scores reﬂect a higher level of depression; 16 is
onsidered the cut score for a clinical level of potential
epression.
ata Analysis
In longitudinal data analyses, missing observations
ose an analytic challenge. In the TCD HRQL study,
ost interviews are missing because of patient illness d
50r death. This poses an additional challenge because
he outcome, quality of life, is related to the reason the
ata are missing. Therefore, the data are not missing
t random, a typical assumption necessary for the
pplication of many statistical methods, but are infor-
atively censored, which means that nonresponse can
e related to both unobserved and observed responses
nd covariates.
The TCD protocol (http://spitﬁre.emmes.com/
tudy/tcd/Protocol/protocol.pdf) speciﬁed an intent-
o-treat analysis of the primary hypothesis of no treat-
ent differences in HRQL: patients would be analyzed
s they were randomized whether or not they received
he randomized treatment assignment. Furthermore,
n anticipation of missing data, the TCD protocol
peciﬁed a consensually developed solution that indi-
iduals who died would received the worst rating for
RQL scale assessments scheduled after their death,
nd individuals who were too ill or otherwise unable
o complete an interview would receive a score of half
he maximum value for each item in the scale. Thus,
he “imputed” data set includes all 314 consenting and
andomized adult subjects (pediatric subjects were
tudied separately). Note that one subject aged 17.75
ears was interviewed as an adult subject. An addi-
ional data set was developed according to the treat-
ent actually received (4 participants were random-
zed to 1 treatment but received the other treatment)
nd without imputation of data to missing partici-
ants. Thus, the “available” data set contains the smaller
umber of participants who completed HRQL inter-
iews at various time points. Table 1 outlines these
articipants and the reasons for interview noncomple-
ion.
Supplementary sensitivity analyses were performed
o assess the effect of assumptions about missing data.
hese analyses considered FACT total scores at ﬁxed
ime points of 100 days, 6 months, 12 months, and 36
onths and 2 summary measures: the area under the
urve over the ﬁrst 12 months and the area under the
urve over the entire 36 months. Three different
odeling approaches were considered: (1) a simple
ixed-effects model assuming a piecewise linear re-
ponse over time, (2) a joint mixed-effects model for
uality-of-life outcome and time to disease progres-
ion or death, and (3) a conditional linear model re-
ating response to the presence of acute GVHD.
A comparison of the joint model versus the simple
ixed-effects model reveals that the missing data
echanism is not ignorable. Speciﬁcally, in the joint
odel for HRQL outcome and time to disease pro-
ression or death, the individual variation in the rate
f change over time (slope random effect) and the log
f the time to disease progression were highly corre-
ated (0.96 for survival and 0.80 for disease-free sur-
ival). It is not surprising that subjects who experience
isease progression or die from their disease would
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Health-Related Quality of Life after BMT
Bave worse HRQL outcomes than the survivors if
heir outcomes could be observed. The results of the
onditional linear model were nearly identical to those
f the simple mixed-effects model.
In summary, the sensitivity analyses showed that
stimates of change in the HRQL response over time
re sensitive to the assumptions about the missing data
echanism but that the 2 treatment arms are similarly
ffected. The result is that the test for treatment
ifferences is insensitive to the assumptions. Because
o differences in HRQL outcomes were seen with
ither the simple or sophisticated analyses performed,
sets of results are presented for the primary analysis:
using imputed scores on all randomized subjects,
ecause this was the analysis speciﬁed in the protocol,
nd 1 using the as-treated subjects.
ESULTS
ata Completeness
The number of adults randomized and the num-
er of interviews conducted and missed by clinical
enter are summarized in Table 2. Large clinical cen-
ers are those that enrolled 50 patients in the trial;
edium centers enrolled 25 to 50 patients; small cen-
ers enrolled fewer than 25 patients. From the 314
able 1. Summary of Adult Interviews by Time (Available Data)
Variable Baseline
o. patients 309
nterview status, n (%)
Interviews performed* 273 (88)
Missed interviews 36 (12)
rimary reason for missed interview (n)†
Patient refusal 15
Ineligible 2
Near death 0
Too ill 2
Scheduling problem 16
Other reasons 1
Thirteen interviews excluded from the available data included 1 b
follow-up interviews on 3 patients with no baseline.
Multiple competing reasons for a missed interview were prioritize
able 2. Summary of Adult Interviews by Center
Clinical
Centers
Randomized
Adults* (n)
Interviews
Submitted Missed Visit
n % Target† n No. Patients
arge 167 351 72 136 78
edium 99 205 76 66 42
mall 48 113 84 21 14
otal 314 669 75 223 134
One patient was aged 17.75 years at randomization.
Target excludes interviews that were not conducted because thespatient had died.
B&MTatients randomized, 669 interviews were conducted.
hree fourths (75%) of required interviews were per-
ormed across all centers. It should be noted that the
rimary report of this trial [7] revealed that the patient
opulation was more educated, afﬂuent, and white
han the general US population. This bias in the data
ould affect HRQL measures in unknown ways, and it
s possible that these characteristics might serve to
uffer patients from adverse outcomes in ways that
ould not be detected from our data. It should also be
oted that participants who experienced relapse were
etained in the HRQL study.
est of the Primary Hypothesis of
reatment-Related HRQL Differences
Wilcoxon tests were conducted to compare FACT 
MT and FACT-G total scores between treatment
rms at 1 year after transplantation. A Wilcoxon test
omparing 1 year FACT-G total scores between treat-
ent arms showed no differences (F  .26; P  .61).
Wilcoxon test comparing 1-year FACT  BMT
otal scores between treatment arms also showed no
ifferences between the TCD arm and the conven-
ional arm (F  .21; P  .65). No differences between
reatment arms were found when FACT-G total scores
ere examined in an analysis of covariance (ANCOVA)
hat adjusted for baseline scores (T  1.19; P  .25),
nd also no differences were found when FACTBMT
otal scores were examined in an ANCOVA that ad-
usted for baseline scores (T  1.37; P  .17). These
nalyses were also conducted by using available data
ather than imputed data in the analyses. No differences
ere found between the 2 arms in these complete-case
nalyses of FACT  BMT and FACT-G scores. All
ACT subscales were analyzed in similar manner, and
o treatment-arm differences at 1 year were noted.
Analyses examining the 1-year scores on the PCS
nd MCS scales of the SF-36 were conducted in the
Time of Interview
All6 mo 1 y 3 y
137 103 81 809
9) 108 (79) 87 (84) 64 (79) 656 (81)
1) 29 (21) 16 (16) 17 (21) 153 (19)
2 4 9 31
0 1 0 4
6 0 0 14
17 5 0 55
4 6 7 47
0 0 1 2
interview from a patient who never received a transplant and 12
lecting the ﬁrst reason among the list in the order presented.100 d
179
124 (6
55 (3
1
1
8
31
14
0
aselineame manner as those for the FACT scores. Speciﬁ-
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6ally, data for the MCS and PCS were examined with
Wilcoxon tests: 1 used the imputed data set, and 1
sed the available data set. Imputed and available data
ere also analyzed in ANCOVAs that were adjusted
or baseline scores. None of the analyses showed sig-
iﬁcance differences between TCD and conventional
rms for MCS and PCS scores (range of P  .27-.91).
Finally, 1-year CES-D scores were analyzed by
sing the same 4 analyses described for the FACT and
F-36. No signiﬁcant differences were found between
CD and conventional arms on the CES-D (range of
 .48-.53). Table 3 presents means and standard
eviations of CES-D, SF-36, and FACT scores at
year after transplantation for the available subjects.
rajectory of HRQL Across Assessments Compared
ith Normative Cancer Patient Data
Data from all participants were compiled for all
ssessment points (day 100, 6 months, 1 year, and
years). The results for the SF-36 compared with
ational normative data for cancer patients are pre-
ented in Figures 1 and 2. In Figure 1, it can be seen
hat mean scores on the MCS at baseline (49.2; SD,
able 3. One-Year Means and Standard Deviations for FACT-BMT,
F-36, and CES-D Scores
Variable
Depleted
(n  39)
Undepleted
(n  48)
All
(n  87)
Mean SD Mean SD Mean SD
ACT-G Total
(28 items) 86.9 15.4 84.6 15.3 85.6 15.3
ACT-BMT Total
(38 items) 116.7 19.7 112.8 20.1 114.6 19.9
F-36 (PCS) 38.4 9.9 37.7 10.8 38.0 10.3
F-36 (MCS) 51.7 8.4 50.0 10.6 50.8 9.6
ES-D 12.3 11.3 13.5 10.8 12.9 11.0
__________ Interviewed Subjects ...........  Cancer Norms
0
10
20
30
40
50
60
70
80
90
100
Time
Baseline 1 Year 3 Years
0
10
20
30
40
50
60
70
80
90
100
igure 1. Interviewed patients compared to normative cancer data,
F-36 MCS [14]. F
52.7) and at 1 year (50.8; SD, 9.6) are similar to the
ancer norms. In Figure 2, the same ﬁndings are
vident for PCS at baseline (mean, 41.5; SD, 10.2) and
t 1 year (mean, 38.0; SD, 10.3). Although there was a
light decrease in function at 3 years for the study
atients, the difference was not statistically signiﬁcant.
Figure 3 presents the FACT BMT scores for all
articipants across all time points compared with can-
er patient normative data. Although the study partic-
pants showed a decrease in function at day 100, there
as a return to normal at 1 year and a retention of
unction at 3 years.
A critical mental health issue is depression, and
igure 4 reveals the CES-D scores across assessment
oints. For this measure, the data reveal that although
epression ﬂuctuated over time, most patients’ scores
ell below the cutoff score of 16.
__________ Interviewed Subjects ...........  Cancer Norms
0
10
20
30
40
50
60
70
80
90
100
Time
Baseline 1 Year 3 Years
0
10
20
30
40
50
60
70
80
90
100
igure 2. Interviewed patients compared to normative cancer data,
F-36 PCS.
__________ Interviewed Subjects ...........  Cancer Norms
0
10
20
30
40
50
60
70
80
90
00
10
20
30
40
50
Time
Baseline 100 Day 6 Month 1 Year 3 Years
igure 3. Interviewed patients compared to normative cancer data,
ACT  BMT.
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Health-Related Quality of Life after BMT
Bomparison of BMT Patient Functioning with
hat of Healthy Adults
General population and cancer patient norms for
he FACT-G have been published [16]. With the
ethod proposed by Brucker et al., the standardized
ffect size was calculated for the TCD trial patients at
year relative to the general US adult population
orms. This was done by ﬁrst adjusting the FACT-G
ean scores by subtracting the Relationship with
octor subscale mean scores for the depleted (6.81)
nd undepleted (7.32) arms, respectively. Then the
ifference of the FACT-G mean scores on the de-
leted and undepleted arms of the study was divided
y the standard deviation of the general adult popu-
ation norms to get an effect size (80.1  76.7 
.3/18.1  0.18). Effect sizes in this range are gener-
lly not considered to be signiﬁcant. Mean FACT-G
cores at 1 year for both study arms were also very
imilar to the adult general population score of 80.1
SD, 18.1) when adjusted for the Relationship with
octor subscale, which was not scored in the norma-
ive population study.
ISCUSSION
The purpose of this study was to examine HRQL
n a randomized trial of TCD BMT versus unmodi-
ed transplantation. At 1 year, the primary outcome
oint, results indicated no differences in HRQL be-
ween patients who received TCD and those who
nderwent conventional treatment procedures. It is
mportant to note that analyses took into account the
atient HRQL at baseline, and differences were con-
rolled. HRQL was assessed by using a generic mea-
ure of HRQL (SF-36), disease-speciﬁc measures
__________ Interviewed Subjects ...........  Cancer Norms
0
4
8
12
16
20
24
28
Time
Baseline 100 Day 6 Month 1 Year 3 Years
Figure 4. CESD-D, interviewed subjects.FACT-G and FACTBMT), and a measure of a d
B&MTritical mental health outcome: ie, depression (CES-
).
The relationship between GVHD and HRQL is
ot direct, because many factors inﬂuence posttrans-
lantation HRQL. Risk factors for poor HRQL after
MT include personal (eg, age, self-concept, and out-
ome expectations) and social factors [17,18], as well as
isease-related factors (eg, diagnosis of GVHD, more
dvanced disease at transplantation, and length of time
ince transplantation) [17,19-21]. Furthermore, regard-
ess of GVHD status, patients may demonstrate psycho-
ogical distress if they experience discordance between
heir pre-BMT expectations for returning to normal and
heir current functional status [19].
Despite its intended beneﬁt in reducing the fre-
uency and severity of acute GVHD, the outcome of
he trial revealed that only acute GVHD incidence
as reduced, whereas chronic GVHD did not differ
etween treatments [7]. It is possible that acute
VHD does not affect HRQL in direct ways, and,
hus, differences in acute GVHD did not inﬂuence
RQL. Additionally, CML relapse was more fre-
uent in the depleted treatment arm, and this differ-
nce may have decreased overall HRQL in the TCD
reatment group. Furthermore, it is possible that
CD facilitates the development of speciﬁc compli-
ations that could hinder HRQL.
Finally, regardless of the early posttransplantation
utcome, most patients—even those doing exception-
lly well—are aware that the question of ultimate
isease control remains unsettled for several years.
his lingering uncertainly about the ultimate out-
ome of transplantation leads to ambiguity in the
ind of patients about how they are doing in the
resent. Therefore, HRQL among BMT patients may
e affected by a number of treatment and disease-
elated factors, as well as the uncertainties surround-
ng the ultimate outcome of the transplantation.
Placing the ﬁndings of this trial in context can
e useful. A cross-sectional study by Andrykowski
t al. [22] compared 662 transplantation survivors re-
ruited through the International Bone Marrow Trans-
lantation Registry/Autologous Blood and Marrow
ransplantation Registry with 158 matched controls.
lthough all survivors reported psychological and inter-
ersonal growth, they also reported poor physical, psy-
hological, and social functioning relative to healthy
ontrols. The authors concluded that transplantation
urvivors are different from healthy controls, especially
n physical functioning measures. This observation is in
ontrast to a study conducted by Bush et al. [23]. This
ongitudinal study examined 415 patients at baseline
nd 117 patients at 4 years of follow-up. The authors
oncluded that typical patients could look forward to
quality of life after transplantation that is broadly
omparable to that of the healthy population. The
ifferent conclusions reached by these studies are
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6ikely due to different populations, different study
esigns (cross-sectional versus longitudinal), and dif-
erent quality-of-life measurement instruments. Also,
he HRQL instruments used may not be able to ac-
ount for the baseline shift that can occur in patients
ver time from the initial onset of disease and trans-
lantation through extended survivorship.
Another study has reported quality-of-life out-
omes in addition to clinical outcomes and costs when
omparing TCD and non-TCD unrelated donor trans-
lantation for hematologic diseases [24]. These authors
nvestigated quality of life before and at 6 and 12 months
fter transplantation. There were no differences in the 2
roups before treatment, and changes over time were
imilar for the 2 treatments. Although the numbers were
mall (12 TCD and 22 immunosuppressive medications
IST]) for HRQL data at 6 months, the median scores
or the PCS from the SF-36 were 32 and 36, respec-
ively, for the TCD and IST arms of the study. The
CS summary scores were 47 and 54, respectively.
hese scores are similar to those in the same study
eported at 12 months, and the complete trajectory is
imilar to the current data.
Our ﬁndings are interesting because they seem to
upport conclusions reached in both the Andrykowski
nd Bush studies. Patients in both treatment arms of
he TCD trial at 1 year have achieved an overall
uality-of-life score (85.6; SD, 15.3) comparable to
hat reported in 1 other study that measured quality of
ife with the FACT instrument at 1 year (89.2; SD,
4.4) [25]. The total score here includes the relation-
hip with doctor (RWD) subscale, currently not in use
n version 4 of the FACT. This mean score (85.6)
inus the RWD (7.3; SD  1.1) is comparable to the
0.1 score reported for the general US adult norms.
his is somewhat surprising in that allogeneic
ransplantation places considerable demands on the
atient’s physical well-being. All patients in the
CD trial were allogeneic transplantation patients,
ompared with other studies with mixed patient pop-
lations.
These ﬁndings do not support the hypothesis that
CD, as deﬁned in this trial, differentially affects
RQL at 1 year after transplantation. Other predic-
ors of outcome from the trial are currently being
nalyzed. Future research might examine more closely
ow patient factors such as age, sex, and psychological
actors (eg, understanding procedures and potential
onsequences, depression, support, and coping style)
ay affect posttransplantation recovery of HRQL and
lso focus on additional time points that may more
ptimally expose the quality-of-life beneﬁts of less
VHD. Although past research has suggested that
CD may be the best method for preventing acute
VHD and although reduction of acute GVHD
hould lead to a substantially better quality of life [1],
ur ﬁndings do not support this assertion. Overall, our
54esults suggest that HRQL at 1 year is no different in
dult patients receiving TCD, as deﬁned in this trial,
ersus conventional transplantation and is therefore
ot a factor to consider when GVHD prophylaxis is
hosen.
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